Review



commercial test to predict preterm birth  (Sera Prognostics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Sera Prognostics commercial test to predict preterm birth
    Commercial Test To Predict Preterm Birth, supplied by Sera Prognostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/commercial+test+to+predict+preterm+birth/pm38579620-131-25-12?v=Sera+Prognostics
    Average 90 stars, based on 1 article reviews
    commercial test to predict preterm birth - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    commercial test to predict preterm birth  (Sera Prognostics)
    90
    Sera Prognostics commercial test to predict preterm birth
    Commercial Test To Predict Preterm Birth, supplied by Sera Prognostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/commercial+test+to+predict+preterm+birth/pm38579620-131-25-12?v=Sera+Prognostics
    Average 90 stars, based on 1 article reviews
    commercial test to predict preterm birth - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    commercial test to predict preterm birth and other obstetric complications  (Sera Prognostics)
    90
    Sera Prognostics commercial test to predict preterm birth and other obstetric complications
    *Equivocal 17P responders: Earliest prior <t>preterm</t> birth was 35–36 weeks, delivered during early term period (37–38 weeks), see text for details
    Commercial Test To Predict Preterm Birth And Other Obstetric Complications, supplied by Sera Prognostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/commercial+test+to+predict+preterm+birth/pmc05086280-272-33-18?v=Sera+Prognostics
    Average 90 stars, based on 1 article reviews
    commercial test to predict preterm birth and other obstetric complications - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    *Equivocal 17P responders: Earliest prior preterm birth was 35–36 weeks, delivered during early term period (37–38 weeks), see text for details

    Journal: American journal of obstetrics and gynecology

    Article Title: Non-response to 17OHP-C for Recurrent Spontaneous Preterm Birth Prevention: Clinical Prediction and Generation of a Risk Scoring System

    doi: 10.1016/j.ajog.2016.07.013

    Figure Lengend Snippet: *Equivocal 17P responders: Earliest prior preterm birth was 35–36 weeks, delivered during early term period (37–38 weeks), see text for details

    Article Snippet: Conflict of Interest/Disclosure Statement : Dr. Sean Esplin serves on the scientific advisory board and holds stock in Sera Prognostics, a private company that was established to create a commercial test to predict preterm birth and other obstetric complications.

    Techniques:

    Demographic factors and prior pregnancy history by 17OHP-C responder status.

    Journal: American journal of obstetrics and gynecology

    Article Title: Non-response to 17OHP-C for Recurrent Spontaneous Preterm Birth Prevention: Clinical Prediction and Generation of a Risk Scoring System

    doi: 10.1016/j.ajog.2016.07.013

    Figure Lengend Snippet: Demographic factors and prior pregnancy history by 17OHP-C responder status.

    Article Snippet: Conflict of Interest/Disclosure Statement : Dr. Sean Esplin serves on the scientific advisory board and holds stock in Sera Prognostics, a private company that was established to create a commercial test to predict preterm birth and other obstetric complications.

    Techniques: Injection

    Multivariable logistic regression model. Shown are factors associated with non-response to 17OHP-C.

    Journal: American journal of obstetrics and gynecology

    Article Title: Non-response to 17OHP-C for Recurrent Spontaneous Preterm Birth Prevention: Clinical Prediction and Generation of a Risk Scoring System

    doi: 10.1016/j.ajog.2016.07.013

    Figure Lengend Snippet: Multivariable logistic regression model. Shown are factors associated with non-response to 17OHP-C.

    Article Snippet: Conflict of Interest/Disclosure Statement : Dr. Sean Esplin serves on the scientific advisory board and holds stock in Sera Prognostics, a private company that was established to create a commercial test to predict preterm birth and other obstetric complications.

    Techniques:

    Risk scoring system to assess likelihood of non-response to 17OHP-C.

    Journal: American journal of obstetrics and gynecology

    Article Title: Non-response to 17OHP-C for Recurrent Spontaneous Preterm Birth Prevention: Clinical Prediction and Generation of a Risk Scoring System

    doi: 10.1016/j.ajog.2016.07.013

    Figure Lengend Snippet: Risk scoring system to assess likelihood of non-response to 17OHP-C.

    Article Snippet: Conflict of Interest/Disclosure Statement : Dr. Sean Esplin serves on the scientific advisory board and holds stock in Sera Prognostics, a private company that was established to create a commercial test to predict preterm birth and other obstetric complications.

    Techniques: